This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Unmet Need in Multiple MyelomaMode of ActionAboutMagentisMM-3 Study OverviewMagnetisMM-3 Study Design and Efficacy OutcomesMagnetisMM-3 Study Safety ProfileMagnetisMM-3 StudySafetyDosingMaterialsVideosSupport & Resources

The content of this website has been produced in line with the ELREXFIO®▼ (elranatamab) Summary of Product Characteristics for Great Britain and Northern Ireland. For ELREXFIO®▼ (elranatamab) Prescribing Information for Great Britain and Northern Ireland click here.

Unmet needs in relapsed or refractory multiple myeloma (RRMM)

MM treatment becomes more complex with each line of therapy, as increased likelihood of treatment resistance leads to shorter remissions1-3

Each multiple myeloma relapse is typically accompanied by:1-4 

  • Increased risk of treatment resistance  
  • Diminished responses to subsequent therapies  
  • Shorter remissions 
  • Reduced quality of life  

In a retrospective analysis of 4,997 patients with MM, average remission times diminished with each line of therapy

Adapted from Yong K, et al.3  
*Paraprotein is the monoclonal protein produced by plasma cells.2  

Analysis Background 

Based on data from a retrospective analysis of patient characteristics, treatment durations and outcomes, and symptom burden in 4,997 patient charts from Belgium, France, Germany, Italy, Spain, Switzerland and the UK. Analysis was performed in 2014.2,3 

Response rate and depth of response typically diminish with each line of therapy5

In a retrospective analysis of 275 patients with MM refractory to a CD38 mAb, subsequent lines of therapy (2nd to 5th) were associated with diminished clinical outcomes compared to 1st line

Adapted from Gandhi UH, et al.

Study Background 

The MAMMOTH study was a US multicentre, retrospective study of 275 patients conducted between January 2017 and June 2018 to investigate the natural history and outcomes of patients with MM refractory to CD38 mAbs.

Patients in the MAMMOTH study were classified into 3 groups:

  • “Penta-refractory” (refractory to 1 anti-cluster of differentiation (CD) 38 monoclonal antibody (mAb) + 2 proteosome inhibitors (PIs) + 2 immunomodulatory drugs (IMiDs)) 
  • “Triple-refractory and quad-refractory” (refractory to 1 anti-CD38 +1 PI + 1 or 2 IMiDs, or 1 anti-CD38 + 1 or 2 PIs + 1 IMiD) 
  • “Not triple-refractory” (refractory to 1 anti-CD38 mAb, and not both of a PI and an IMiD).
ReferencesCD38: cluster of differentiation 38; CR: complete response; IMiD: immunomodulatory drug; mAb: monoclonal antibody; MM: multiple myeloma; mTTP: median time to progression; ORR: objective response rate; PI: proteasome inhibitor; PR: partial response; RRMM: relapsed or refractory multiple myeloma; SCR: stringent complete response; VGPR: very good partial response

References:

Shah N, et al. Leukemia. 2020;34:985-1005.Bird SA and Boyd K. Palliat Care Soc Pract. 2019;13:1-13.Yong K, et al. Br J Haematol. 2016;175:252-264.Ramsenthaler C, et al. BMC Cancer. 2016;16:427.Gandhi UH, et al. Leukemia. 2019;33:2266-2275. 
Mode of actionELREXFIO® is a humanised BCMA-CD3-directed bispecific antibody Read moreLoadingMagnetisMM-3 overviewEfficacy and safety reported from the BCMA-directed therapy-naïve cohort of the Phase 2 MagnetisMM-3 study (n=123) Read moreLoading
PP-L1A-GBR-0020. March 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​